Gelonghui, May 9 丨 Recently, Xinhua Healthcare (600587.SH) announced its 2022 financial report and 2023 quarterly report. According to the CaiTong Securities Research Report, the company's performance continues to grow at a high rate. The profitability of the medical device sector has increased significantly under the increasing share of consumables, driven by new businesses, and cost control. Among them, new businesses in the pharmaceutical equipment sector have made breakthrough progress. The bank pointed out that Xinhua Healthcare is a key company for state-owned enterprise reform in Shandong. Earlier, the company introduced employee equity incentives. The target net profit for 2022-2024 is no less than 360 million yuan, 510 million yuan, and 570 million yuan. The completion of 2022 results is far higher than the equity incentive target. At the same time, the majority shareholders participated in the company's promotion at a large rate of 23.38 yuan/share, and employees' interests were tied to shareholders' interests. The company is expected to achieve operating income of 9998/110.19/12.138 billion yuan in 2023-2025, and net profit of 686/879/1,058 million yuan. The corresponding PE was 21/17/14 times respectively. The corresponding PE was covered for the first time, giving it an “increase in holdings” rating.